Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06755541

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)

Sponsor: Xijing Hospital of Digestive Diseases

Conditions Primary Biliary Cholangitis (PBC)

Interventions Fenofibrate in Combination With Ursodeoxycholic Acid

Updated 2 times since 2025 Last updated: Jan 6, 2026 Started: Jan 30, 2024 Primary completion: Dec 31, 2035 Completion: Dec 31, 2035

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary Biliary Cholangitis (PBC) and is currently actively recruiting participants. Xijing Hospital of Digestive Diseases leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Feb 2025 — Feb 2026 [monthly]

Recruiting PHASE3

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xijing Hospital of Digestive Diseases

Data source: Xijing Hospital of Digestive Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China